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Progressive multiple sclerosis is associated with metabolic failure of the axon and excitotoxicity that leads to chronic neuro-
degeneration. Global sodium-channel blockade causes side effects that can limit its use for neuroprotection in multiple sclerosis.
Through selective targeting of drugs to lesions we aimed to improve the potential therapeutic window for treatment. This was
assessed in the relapsing-progressive experimental autoimmune encephalomyelitis ABH mouse model of multiple sclerosis using
conventional sodium channel blockers and a novel central nervous system-excluded sodium channel blocker (CFM6104) that
was synthesized with properties that selectively target the inflammatory penumbra in experimental autoimmune encephalomy-
elitis lesions. Carbamazepine and oxcarbazepine were not immunosuppressive in lymphocyte-driven autoimmunity, but slowed
the accumulation of disability in experimental autoimmune encephalomyelitis when administered during periods of the inflam-
matory penumbra after active lesion formation, and was shown to limit the development of neurodegeneration during optic
neuritis in myelin-specific T cell receptor transgenic mice. CFM6104 was shown to be a state-selective, sodium channel blocker
and a fluorescent p-glycoprotein substrate that was traceable. This compound was 490% excluded from the central nervous
system in normal mice, but entered the central nervous system during the inflammatory phase in experimental autoimmune
encephalomyelitis mice. This occurs after the focal and selective downregulation of endothelial p-glycoprotein at the blood–
brain barrier that occurs in both experimental autoimmune encephalomyelitis and multiple sclerosis lesions. CFM6104
significantly slowed down the accumulation of disability and nerve loss in experimental autoimmune encephalomyelitis.
doi:10.1093/brain/awt324 Brain 2013: Page 1 of 17 | 1
Received June 21, 2013. Revised September 26, 2013. Accepted September 30, 2013.
 The Author (2013). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
 Brain Advance Access published November 27, 2013
 at Queen M
ary, University of London on November 28, 2013
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Therapeutic-targeting of drugs to lesions may reduce the potential side effect profile of neuroprotective agents that can influ-
ence neurotransmission. This class of agents inhibit microglial activity and neural sodium loading, which are both thought to
contribute to progressive neurodegeneration in multiple sclerosis and possibly other neurodegenerative diseases.
Keywords: multiple sclerosis; animal models; experimental allergic encephalomyelitis; neural repair
Abbreviation: EAE = experimental autoimmune encephalomyelitis
Introduction
Multiple sclerosis is the major cause of non-traumatic disability in
young adults (Compston and Coles, 2008). It is clear that relapsing
multiple sclerosis can be controlled by the action of peripherally-
active immunosuppressive agents that reduce CNS atrophy
(Gunnarsson et al., 2011; Marta and Giovannoni, 2012). These
serve to limit waves of inflammatory cells entering the CNS from
the blood that are manifest in relapsing disease in humans and in
experimental autoimmune encephalomyelitis (EAE) animal models
of multiple sclerosis (Allen et al., 1993; Lassmann, 2013). These
cause focal lesions that are characterized by demyelination and
variable degrees of axonal loss, gliosis and microglial activation.
The microenvironment in lesions is believed to progressively
damage axons and make them susceptible to chronic degeneration
(Pryce et al., 2005; Hampton et al., 2008), which underpins the
accumulation of chronic disability (Lassmann, 2013). This second-
ary progression appears to be unresponsive to peripheral immuno-
suppression in both multiple sclerosis and EAE and is currently
untreatable (Coles et al., 1999; Pryce et al., 2005; Dutta and
Trapp, 2011; Al-Izki et al., 2012).
Although, the precise mechanisms of axonal pathology are un-
proven, axonal pathology in acute multiple sclerosis lesions is asso-
ciated with macrophage and glial cell activation, excitotoxicity and
loss of metabolic support (Dutta and Trapp, 2011; Lee et al.,
2012; Parpura and Verkhratsky, 2012). Demyelination also leads
to neuronal sodium and calcium channel upregulation and
increased energy demands that leave demyelinated axons vulner-
able to further damage (Craner et al., 2004). Voltage-gated
sodium channels (Nav) are redistributed from the nodes of
Ranvier along demyelinated axonal segments to maintain neural
conduction (Craner et al., 2004). This facilitates sodium loading
that is compounded by loss of activity of energy-dependent
sodium pumps following mitochondrial dysfunction secondary to
a complex inflammatory cascade (Dutta and Trapp, 2011). This
can lead to the formation of toxic levels of axoplasmic calcium
(Kapoor et al., 2003; Dutta and Trapp, 2011), which trigger fur-
ther neuroaxonal damage. This, in conjunction with and altered
astrocytic control of neurotransmitter balance, leads to progressive
disability that no longer responds to systemic immunosuppression
(Dutta and Trapp, 2011; Lee et al., 2012; Parpura and
Verkhratsky, 2012). Although these mechanisms highlight poten-
tial therapeutic targets (Fern et al., 1993; Waxman, 2008), many
of them are involved in normal nerve function; inhibiting their
function may therefore be associated with side effects that can
limit their clinical use (Kapoor et al., 2010; Gnanapavan et al.,
2013). This is particularly a problem in progressive multiple
sclerosis where accumulating nerve loss reduces compensatory or
reserve capacity and lowers the threshold for side effects from
drugs that alter neurotransmitter function. There is an urgent,
unmet need to find new treatments for progressive multiple
sclerosis.
Studies in myelin oligodendrocyte glycoprotein (MOG) peptide-
induced EAE in C57BL/6 and Biozzi ABH mice have shown that
Nav blockers can ameliorate the development of neurological dis-
ease (Lo et al., 2003; Black et al., 2006, 2007). In many instances
the treatment benefit of Nav blockers could be attributed to im-
munosuppression that prevented lesion formation and the devel-
opment of disease (Craner et al., 2005; Black et al., 2007).
However, in Biozzi ABH mice, the myelin peptide used to induce
disease to examine the influence of carbamazepine (Black et al.,
2007) was subdominant even within the MOG protein, which in
itself is not the major encephalitogenic auto-antigen (Amor et al.,
1994; Pryce et al., 2005; Smith et al., 2005). After active sensi-
tization with spinal cord homogenate in Freund’s adjuvant the
initial paralytic attack is inflammatory, but is not associated with
significant demyelination and neuroaxonal loss. The latter occurs
following the development of spontaneous or induced-relapsing
disease (Baker et al., 1990; Hampton et al., 2008; Jackson
et al., 2009; Al-Izki et al., 2012). This stage of disease in the
ABH model allows one to discriminate between the effects of
therapies that target both immunosuppression and/or neuropro-
tective mechanisms. Neuroprotection is seen by the slower accu-
mulation of residual neurological deficits and slower loss of motor
control on RotaRod activity, which have a good correlation with
spinal nerve content (Al-Izki et al., 2012).
As demyelinated lesions centre around the vasculature (Baker
et al., 1990; Lassmann, 2013), we hypothesized that it would be
possible to use blood–brain barrier activities, notably exploiting the
actions of energy-dependent, adenosine triphosphatase binding cas-
sette (ABC) transporters, such as p-glycoprotein (Miller et al., 2008),
to selectively target potentially neuroprotective agents to multiple
sclerosis lesions. We show this activity using a novel CNS-excluded
Nav blocker, which is a p-glycoprotein substrate, and was targeted
to lesions after the selective loss of p-glycoprotein that occurs in
both multiple sclerosis and EAE lesions.
Materials and methods
Multiple sclerosis tissue
Brain tissue samples were obtained from the Netherlands Brain Bank.
The Netherlands Brain Bank received permission to perform autopsies
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for the use of tissue and for access to medical records for research
purposes from the Ethical Committee of the VU University Medical
Centre, Amsterdam, The Netherlands. A total of 10 paraffin-
embedded tissue blocks from patients with multiple sclerosis, contain-
ing active, chronic active and chronic inactive lesions, and one white
matter block from six different donors without neurological disease
were selected. Normal-appearing white matter and lesions in white
matter were selected on the basis of post-mortem MRI. All patients
with multiple sclerosis and control subjects, or their next of kin, had
given informed consent for autopsy and use of their brain tissue for
research purposes. Analysis of tissue was supported by ethical review
panels within The Netherlands and UK (REC 08/H0722/26).
Animals
Adult female (6–8 weeks), pathogen-free, Biozzi ABH mice and
C57BL/10.RIII mice were purchased from Harlan UK Ltd, or
male and female ABH mice were bred at Queen Mary University
of London. C57BL6.Cg-Tg (Thy1-CFP)23Jrs.Tg (Tcra2D2,
Tcrb2D2)1Kuch/J transgenic mice, which express a neuronally-
restricted, Thy1-promoter driven expression of cyan fluorescent pro-
tein (CFP) that is limited to retinal ganglion cells within the retina
(Feng et al., 2000) and a H-2b-restricted MOG-specific T cell receptor
(Bettelli et al., 2003; Guan et al., 2006), were from stock bred at
Queen Mary University of London (Lidster et al., 2013). Methods of
housing, allocation to groups and other reporting elements including
blinding, relevant to the ARRIVE guidelines have been reported previ-
ously (Al-Izki et al., 2012). All procedures were approved by the local
ethical review processes and were performed in accordance with the
UK Animal (Scientific Procedures) Act 1986.
Chemicals
Carbamazepine, oxcarbazepine, memantine hydrochloride and mino-
cycline hydrochloride were purchased from Sigma Aldrich. CFM6104
[N-((5-(2-(2-(1h-imidazol-1-yl)ethyl)-2h-indazol-3-yl)-1,2,4-oxadiazol-
3-yl)methyl)-3-methylbenzamide] is a novel, non-selective, state-
dependent sodium channel blocker. The synthesis will be described
elsewhere (Browne et al., submitted for publication). This has no
detectable activity on active receptor subtypes (IC504 30mM), but
had modest activity (IC50 = 20–25 mM) on inactive Nav1.1, Nav1.2,
Nav1.5, Nav1.6, Nav1.7 receptors (Browne et al., submitted for
publication). CFM6104 was dissolved in a 1:1 solution of dimethyl
sulphoxide and PBS and allowed to cool before administration
intraperitoneally, or dissolved in ethanol:cremophor:PBS 1:1:18.
Minocycline hydrochloride was adjusted to pH 7, using 10 N sodium
hydroxide before use. These were administered either daily just before
or after the anticipated onset of relapsing disease.
In vivo T cell proliferation assays
The contact sensitizer 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one
(oxazolone, OX, Sigma) was dissolved (25 mg/ml) in 4:1 acetone:olive
oil. Mice (n = 3 per group) received epicutaneous application of either
25 ml of 2.5% oxazolone or acetone:olive oil on the dorsum of the ear
on Day 0 (O’Neill et al., 1992). The draining auricular lymph nodes
were removed 3 days later and the induced proliferative response was
assessed as previously described. Briefly, 5  105 cells per well were
cultured in RPMI-1640 medium with glutamate (Gibco, Invitrogen),
supplemented with 0.5 mM sodium, in round-bottomed 96-well plates
overnight at 37C in a humidified atmosphere of 5% CO2. T cell
proliferation was assessed using the CellTiter 96 AQueous
Non-Radioactive Cell Proliferation Assay according to the manufac-
turer’s instructions (Promega) and the absorbance was recorded at
490 nm. Animals received daily intraperitoneal injections of either
vehicle or CFM6104 from Day 0–3.
Induction of relapsing-progressive
experimental autoimmune
encephalomyelitis
Mice were injected subcutaneously with 1 mg freeze-dried mouse
spinal cord homogenate in Freund’s adjuvant on Days 0 and 7 as
described previously (Al-Izki et al., 2012). After the initial paralytic
disease and subsequent remission, a relapse was induced by a further
injection of spinal cord homogenate in Freund’s adjuvant on Day 28 to
induce a relapse 7 days later (Al-Izki et al., 2012). Studies were ran-
domized, blinded and powered as described previously (Al-Izki et al.,
2012). Neurological scores were graded as: 0 = normal; 1 = limp tail;
2 = impaired righting reflex; 3 = hindlimb paresis; 4 = complete hind-
limb paralysis; and 5 = moribund/death (Al-Izki et al., 2012). Motor
control and co-ordination was assessed on an accelerating (4–40 rpm,
accelerating at 6 rpm/25 s) RotaRod (ENV-575 M, Med Associates Inc.)
as described previously (Al-Izki et al., 2012). This was performed 1 day
before induction of relapse and 1 day before termination of the
experiment on Day 49–50. RotaRod assessment was performed
blinded to treatment. Animals were randomized to vehicle or
treatment based on their RotaRod scores.
At the end of the experiment the spinal cord was removed and an
ELISA for heavy chain neurofilament on spinal cord was performed
and total nerve content of each spinal cord was estimated following
calibration against neurofilament protein standards as described
previously (Jackson et al., 2005).
Induction of experimental
autoimmune uveitis
C57BL/10.RIII mice were injected subcutaneously with 25 mg interpho-
toreceptor binding peptide residues 161–182 in Freund’s adjuvant on
Days 0 and 7 as described previously (Hankey et al., 2001). On Day
21 post-induction animals were killed and eyes were removed, fixed,
wax embedded and 5 mm sections through the optic nerve head were
stained with haematoxylin and eosin. Sections were scored blinded to
treatment on a 0–6 scale to assess the degree of cellular infiltration
and a 0–5 scale to assess retinal nerve damage as described previously
(Hankey et al., 2001).
Induction of optic neuritis mouse model
Optic neuritis was induced in C57BL/6-.Cg-Tg (Thy1-CFP)23Jrs.Tg
(Tcra2D2, Tcrb2D2)1Kuch/J transgenic mice after administration of
150 ng Bordetella pertussis toxin (Sigma Aldrich) in PBS on Days 0
and 2 (Bettelli et al., 2003; Lidster et al., 2013) Subclinical EAE and
optic neuritis within the optic nerve was augmented following the
injection of 250mg Z12 rat IgG2b mouse myelin oligodendrocyte-
specific demyelinating antibody (Piddlesden et al., 1993; Lidster
et al., 2013) on Day 14. Animals were injected daily on Days 0–21
with the compounds. Animals were killed on Day 21 post-induction
and eyes were enucleated and immersed in 4% paraformaldehyde
(Sigma Aldrich) in PBS pH 7.4 overnight. The retinas were dissected
and the cornea, sclera, lens, hyaloid vasculature and connective tissue
were removed in 2 normal strength PBS. Four radial incisions were
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cut around the retinas and flat mounts were mounted onto slides and
cover-slipped with anti-fade glycerol (CitiFluor Ltd). The retinal flat
mounts were imaged by fluorescent microscopy and retinal ganglion
cells density was calculated by counting CFP expressing retinal gan-
glion cells using stereology software with a fractionator probe and
the number cells in the four quadrants around the optic nerve head
counted (Lidster et al., 2013). The results are expressed as
mean  standard error of the mean (SEM).
Liquid chromatography–mass
spectroscopy
Pharmacokinetic studies on plasma and brain samples using liquid
chromatography-mass spectroscopy (LC-MS/MS) with a sensitivity of
3 ng/ml, was performed by Merck Serono. In addition plasma and
spinal cords were harvested from ABH mice 30 min after the intraper-
itoneal injection of 10 mg/kg CFM6104 in ethanol:cremophor:PBS
1:1:18. Spinal cords were homogenized in 2 ml eppendorf tubes
using a 5 mm steel bead and TissueLyzer-II (Qiagen) set at 25 Hz for
5 min. Twenty microlitres of the homogenate or plasma was extracted
by 100 ml acetonitrile (with internal standard, coumaphos). Samples
were then incubated on ice for 30 min, centrifuged and the super-
natant was analysed using UPLC-MS/MS. Analytes were resolved
using an Accela UPLC (Thermo Scientific) equipped with 1.7 mm PFP
Kinetex 2.1  50 mm UPLC column (Phenomenex) and a mobile phase
gradient of buffer A (water + 0.1% formic acid) and buffer B (aceto-
nitrile + 0.1 formic acid) at a flow rate of 500 ml/min. Eluting com-
pounds of interest were detected using a TSQ Vantage mass
spectrometry system (Thermo Scientific). The optimum transitional
daughter ions mass of each analyst were as follows: CFM6104 m/z
414.1 ! 239.1 and coumaphos m/z 363.3 ! 227. The sensitivity was
1 ng/ml.
P-glycoprotein assay
Assessment of vascular permeability was performed using the Pgp-
GloTM assay (Promega) containing recombinant human ABCB1 in
membranes according to the manufacturer’s instructions. Briefly, sam-
ples were preincubated with ATP before incubation with 100 mM com-
pound or positive control. The residual ATP was assayed by luciferin
bioluminescence. In addition, monolayer permeability and efflux was
assessed in a bi-directional transport assay by Merck Serono using
CacoReadyTM (ReadyCell SL). Briefly, differentiated and polarized
Caco-2 cell barriers were grown on polycarbone microporous filters
in a 24-well format. One micrometre compounds were incubated for
120 min pH 7.4/7.4 apical/basolateral after apical or basolateral appli-
cation and basolateral or apical sampling, respectively, in the presence
or absence of 1 mM cyclosporin A, which is a p-glycoprotein inhibitor.
Drug concentrations were assessed by LC-MS/MS using an API
5500-Trap.
Immunohistochemistry
Formalin-fixed paraffin-embedded mouse and human tissue was sec-
tioned at 5 mm. Human tissue was stained for proteolipid protein (PLP,
clone plpc1, Serotec Ltd), HLA-DR (clone LN3, Dako), p-glycoprotein/
CD243 (clone C219, Abcam), breast cancer resistance protein (BCRP/
CD338, clone 6D170, US Biological) and the endothelial marker glu-
cose transporter-1 (Glut-1; a kind gift from Jack van Horssen, VUMC).
Sections were deparaffinized in xylene and rehydrated through graded
alcohol into distilled water. Endogenous peroxidase activity was
quenched using 0.3% hydrogen peroxide in methanol. For HLA-DR,
p-glycoprotein, BCRP (now known as ABCG2) and Glut-1 detection,
slides were rinsed with distilled water and transferred to citric acid for
heat-induced antigen retrieval. After microwave irradiation for 5 min
on the high setting and for 10 min on the medium setting, slides were
cooled to room temperature and rinsed in PBS. Serial sections were
incubated overnight with either anti-HLA-DR (1:100), proteolipid pro-
tein (1:500), p-glycoprotein (clone C219, 1:50); BCRP (1:400); Glut-1
(1:1000). Slides were incubated with Envision Kit horseradish peroxid-
ase-labelled anti-mouse/rabbit Ig (Dako) for 30 min at room tempera-
ture, and finally diaminobenzidine tetrachloride. Between incubation
steps, sections were thoroughly washed with PBS. After a short rinse
in tap water sections were incubated with haematoxylin for 1 min and
extensively washed with tap water for 10 min. Finally, sections were
dehydrated with ethanol followed by xylol and mounted with Entellan
(Merck). All antibodies were diluted in PBS containing 0.1% bovine
serum albumin (Boehringer-Mannheim), which also served as a nega-
tive control. Immunofluorescence was carried out on sections from
three patients with multiple sclerosis to depict Glut-1, p-glycoprotein
and cell nuclei with DAPI. After antigen retrieval and blocking for 1 h
with 5% normal goat serum, the sections were incubated with
p-glycoprotein (1:20) and Glut-1 (1:50) overnight at room tempera-
ture. The sections were then rinsed in PBS and the secondary antibo-
dies (goat anti-rabbit Ig Alexa Fluor 488 and goat anti-mouse Ig
Alexa Fluor 594) applied for 1 h. After washing in PBS, sections
where incubated with 0.5% Sudan Black (Sigma) and nuclei visualized
with DAPI, washed and mounted in glycerol/PBS. This protocol was
also used on formalin fixed-snap-frozen mouse tissues from chronic
secondary progressive EAE tissues with the exception of a mouse-
on-mouse blocking step using CleanVision (Immunologic).
Statistical analysis
The neurological scores are presented as the mean daily neurological
score  SEM. Differences in scores in EAE and experimental autoim-
mune uveitis were assessed using Mann-Whitney U statistics. The
parametric data, including RotaRod and retinal ganglion cells
number, were assessed using a student’s t-test or one-way ANOVA
incorporating tests for equality of variance using Sigmastat/Sigmaplot
software (Systat Software, Inc.).
Results
Nav blockade is neuroprotective in
central nervous system autoimmunity
Spinal cord homogenate-induced relapsing-progressive disease in
Biozzi ABH mice was used to examine the neuroprotective influ-
ence of Nav blockage. When drug administration was avoided
during the sensitization periods, there was no evidence of any
marked immunosuppressive effect of administration intraperitone-
ally of either 1 mg/kg or 10 mg/kg carbamazepine. All animals
developed EAE with comparable high severity (Fig. 1A). This indi-
cated marked inflammatory cell recruitment into the CNS (Allen
et al., 1993; Jackson et al., 2009), in contrast to that occurring
with T cell immunosuppressive agents (Watson et al., 1991; Baker
et al., 1992; O’Neill et al., 1992, 1993). The maximum disease
score of animals in relapse was comparable between vehicle and
carbamazepine-treated animals (Fig. 1A and B); however, the
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Figure 1 Low-dose carbamazepine inhibits the accumulation of neurological deficit during CNS autoimmunity. (A and B) ABH mice
were injected with mouse spinal cord homogenate in Freund’s adjuvant on Days 0 and 7 post-induction (p.i.) to induce EAE and on Day 27
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residual deficit during remission from relapse was significantly
reduced (P5 0.001). Vehicle-treated mice remitted to a score of
3.1  0.2 compared with 0.8  0.1 (1 mg/kg) or 0.8  0.3
(10 mg/kg) for carbamazepine-treated animals. Although there
was no statistically significant difference in the scores of groups
before treatment onset it appeared that following randomization
to the RotaRod score, there were more animals with residual limb
paresis in the vehicle group after unblinding (Fig. 1A). As a con-
sequence of this, for subsequent experiments we set an exclusion
criterion such that animals with residual limb paresis after the ini-
tial attack were not entered into the randomization or treatment
processes. Applying this criterion to remove animals from the
experiment (Fig. 1A) such that the score before treatment onset
was 0.5  0.0, the data, however, still demonstrated that there
was no difference in the severity of the relapse [3.6  0.4 (vehicle)
verses 3.6  0.2 (10 mg/kg) and 3.7  0.1 (1 mg/kg) carbamaze-
pine] but carbamazepine-treated animals demonstrated a signifi-
cantly better recovery [2.6  0.7 (vehicle) verses 0.8  0.3
(10 mg/kg) and 0.5  0.0 (1 mg/kg) carbamazepine (P50.05)].
This recovery was mirrored in the motor functional analysis
using the RotaRod whereby animals treated with carbamazepine
were able to stay on the RotaRod significantly (P50.001)
longer (1 mg/kg 191.6  25.3 s, 10 mg/kg 131  17.1 s) than
those treated with vehicle (35.4  11.6 s) after 14 days of
treatment.
These data suggest that treatment does not stop the cause of
disease or lesion formation indicating a lack of lymphoid cell-
induced immunosuppression (Baker et al., 2011). In an additional
model (Fig. 1C), experimental autoimmune uveitis in C57BL/
10.RIII mice (Hankey et al., 2001), daily intraperitoneal injection
from Day 8–22 of 10 mg/kg carbamazepine limited the accumu-
lation of retinal nerve damage in the eye (P50.02), without sig-
nificantly influencing the degree of immune infiltration with the
retina (Fig. 1C). This was more neuroprotective than similar deliv-
ery of 10 mg/kg memantine (a weak N-methyl-D-aspartate glu-
tamate receptor antagonist) or minocycline (microglial-inactivating
antibiotic).
Time window for Nav blockers to
influence the inflammatory penumbra
While treatment was therapeutic as animals were already sensi-
tized and disease had manifested before therapy was initiated
(Fig. 1A and B), the protective effect of administration after dis-
ease onset was investigated (Fig. 2). Carbamazepine and oxcarba-
zepine were administered at various times after the onset of signs
and the influence on recovery assessed. In the first set of experi-
ments, treatment with carbamazepine, oxcarbazepine or vehicle
was initiated at the onset of signs (Day 0) or 2 days later and
continued until the end of the experiment Day 50 post-
induction. Animals treated with carbamazepine and oxcarbazepine
from Day 0 (day of relapse onset) had significantly less disability
(P5 0.01 and P50.05, respectively) than those treated with
vehicle control as assessed using the neurological scoring system.
This improvement was also seen in the RotaRod, in which animals
treated with both sodium channel blockers performed significantly
(P5 0.001) better than those treated with vehicle control. When
treatment was delayed a further 2 days after onset of relapse, the
beneficial effect on the neurological score was not as pronounced,
but there was some improvement in RotoRod scores (Fig. 2B and
D). In an additional experiment, treatment with oxcarbazepine
was delayed until Day 4 post disease-onset (Fig. 2E and F).
At this time point, 4 days post disease-onset, the drug had no
effect on clinical score or RotaRod performance (Fig. 2E and F).
Animals to be treated were selected before randomization to treat-
ment on the basis that their weight had stabilized or improved
from the previous day. Paralysed animals that are gaining
weight are beginning to remit and have a reduction in blood–
brain barrier dysfunction manifest as cellular recruitment and
plasma protein extravasation (Al-Izki et al., 2012). This suggests
that the Nav blocking compounds were most active during
lesion formation and periods of blood–brain barrier dysfunction.
Once the natural regulatory mechanisms that limit relapse
were initiated, Nav blockage failed to augment the recovery
response.
Although RotoRod activity strongly correlates with spinal
nerve loss (Al-Izki et al. 2012), unfortunately it was not possible
to measure spinal cord nerve content for technical reasons.
Therefore, to demonstrate the neuroprotective effects of these
compounds histologically, additional experiments were per-
formed using a transgenic mouse model of multiple scler-
osis that develops optic neuritis, where EAE typically remains
subclinical after stimulation of MOG-specific transgenic T cell
receptors (Lidster et al. 2013). As a consequence of auto-
immunity to MOG within the optic nerve, consequent retinal
ganglion cells loss within the retina can subsequently be
Figure 1 Continued
post-induction to induce a relapse. Animals were injected daily intraperitoneally with either 0.1 ml vehicle (black bar n = 7), 1 mg/kg (grey
bar n = 7) or 10 mg/kg (white bar n = 7) carbamazepine from Day 33 onwards. Animals were monitored for the development of clinical
disease and the results represent: (A) The mean maximal clinical score, during the initial acute attack Days 15–20 and the clinical relapse
Days 34–40, or the mean minimal clinical score during remission from paralytic attacks. (B) The time taken to fall from an accelerating
RotaRod was monitored pretreatment on Day 28 or on Day 48 post-disease induction, when the experiment was terminated. (C) B10.RIII
mice were injected with interphotoreceptor binding peptide in Freund’s adjuvant on Days 0 and 7. Animals were sacrificed on Day 21 and
the eyes were fixed, sectioned at the level of the optic nerve head and stained with haematoxylin and eosin. Animals were treated daily
intraperitoneally from Day 8–21 with either vehicle (n = 5), 10 mg/kg memantine (n = 5), 10 mg/kg minocycline (n = 5) or 10 mg/kg
carbamazepine (n = 6). These were scored to assess the degree of ocular infiltration on a 0–6 scale, where typically peak infiltration score
of 4–5 occurs Day 10 and were scored for retinal structural damage on a 0–5 scale, which typically reaches a plateau by Day 16
onwards. Results represent the mean  SEM score. *P50.05 compared with vehicle-treated animals. **P5 0.02 compared with vehicle.
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monitored using fluorescence microscopy to detect CFP
expressing retinal ganglion cells (Fig. 3A–D). Sodium channel
blockage with either 10 mg/kg carbamazepine or
oxcarbazepine (Fig. 3A, B and D) both significantly (P5 0.05)
limited the amount of nerve loss compared to the influence of
vehicle (ECP) occurring as a consequence of optic neuritis
(Fig. 3C and D).
Selective loss of energy-dependent
efflux transporters during
neuroinflammatory disease
The clinical use of Nav channel blockers in multiple sclerosis can be
associated with the development of neurological side effects at
doses below those used for anti-convulsive activity in epilepsy
Time post induction (Days)
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
M
ea
n
 
cl
in
ic
al
 
sc
or
e 
± 
SE
M
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Vehicle 
Oxcarbazepine at  onset
Oxcarbazepine at Day 2 Remission 1
(Pre-Treatment)Tim
e 
of
 
on
 
Ac
ce
le
ra
tin
g 
 
Ro
ta
Ro
d 
±
 
SE
M
 
(s)
0
50
100
150
200
250
300
Vehicle
Oxcarbazepine at onset
Oxcarbazepine at Day 2
Remission 2
(Post-Treatment)
**
***
Time post induction (Days)
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
M
ea
n
 
cl
in
ic
al
 
sc
or
e 
± 
SE
M
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Vehicle
Oxcarbamazepine at Day 4
Ti
m
e
 
o
n
 A
cc
el
er
at
in
g 
Ro
ta
R
o
d 
± 
SE
M
 
(s)
0
50
100
150
200
250
300
vehicle 
Carbamazepine at onset
Carbamazepine at Day 2 
Remission 1
(Pre-Teatment)
Remision 2
(Post-Treatment)Time post induction (Days)
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
M
ea
n 
cl
in
ic
al
 
sc
or
e 
± 
SE
M
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Carbamazepine at onset
Carbamazepine at Day 2 
Vehicle 
Ti
m
e 
on
 
Ac
ce
le
ra
tin
g 
Ro
ta
R
od
 ±
 S
EM
 
(s)
0
50
100
150
200
250 Vehicle
Oxcarbazepine at Day 4 
Remission 1
(Pre-Treatment)
Remission 2 
(Post-Treatment)
A B
C D
E
F
**
**
**
Figure 2 Carbamazepine and oxcarbazepine inhibit the accumulation of neurological deficit days following onset of signs during EAE.
ABH mice were injected with 1 mg mouse spinal cord homogenate in Freund’s adjuvant on Days 0 and 7 post-induction to induce EAE and
this was repeated on Day 27 post-induction to induce a relapse. Animals were injected daily intraperitoneally with either vehicle or 10 mg/
kg carbamazepine or oxcarbazepine at the (A–D) onset of signs on Day 35 (onset) or 2 days (Day 2) later, or (E and F) 4 days (Day 4) after
onset of signs of relapse. Animals were monitored for the development of clinical disease and the results represent: (A, C and E) the mean
daily clinical score after induction of relapse. (B, D and F) The time taken to fall from an accelerating RotaRod was monitored pretreatment
on Day 25 or on Day 48 post-disease induction, when the experiment was terminated. Results represent the mean  SEM of eight animals
per group. *P5 0.05, **P50.01, ***P5 0.001 compared with vehicle-treated animals.
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(Kapoor et al., 2010). Therefore, by selectively targeting potential
neuroprotective drugs to active lesions, it may be possible to
improve the therapeutic window for this class of drugs.
Although the nature of blood–brain barrier dysfunction is varied,
it is well-known that this is associated with leakage of cells and
plasma proteins in EAE and multiple sclerosis (Butter et al., 1991;
Al-Izki et al., 2012). One aspect that contributes to this—as
shown here—is the selective loss of p-glycoprotein (ABCB1)
within lesions. This occurs both in EAE (Fig. 4) and multiple scler-
osis (Fig. 5) lesions. In comparison with vascular p-glycoprotein
expression in normal mice (Fig. 4A), p-glycoprotein was selectively
lost in active lesions during relapsing disease (Fig. 4B and C) in
comparison with BCRP (now known as ABCG2, Fig. 4D) and com-
pared with non-inflamed tissues (Fig. 4C and E–K). P-glycoprotein
was lost from the vasculature (Fig. 4H–K) as shown using double-
labelling of p-glycoprotein with Glut-1 on endothelia (Fig. 4L–N).
This vascular loss of p-glycoprotein remained during post-relapsing
secondary progressive EAE (Fig. 4L–N) and in comparison with
normal brain tissue (Fig. 5A) and normal-appearing white matter
in multiple sclerosis (Fig. 5B), p-glycoprotein was also absent from
the vasculature in chronic inactive in multiple sclerosis lesions
(Fig. 5C and D). Interestingly there was an upregulation of astro-
cytic p-glycoprotein in such chronic lesions (Fig. 5D) and non-
vascular p-glycoprotein expression seemed to occur in EAE lesions
(Fig. 4B and L–N). Again, in humans there was selective loss of
p-glycoprotein in contrast to vascular expression of BCRP in mul-
tiple sclerosis lesions (Fig. 5E). Double-labelling of p-glycoprotein
with endothelial Glut-1 (Fig. 5F–K) demonstrated vascular expres-
sion of p-glycoprotein in vessels in normal-appearing white matter
(Fig. 5F–H), which was reduced or lost in lesions (Fig. 5I–K)
although it was detected in non-Glut-1-positive cells even in
active multiple sclerosis lesions (Fig. 5J and K).
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Figure 3 Carbamazepine and oxcarbazepine inhibits the development of neurogeneration. C57BL/6 transgenic mice expressing MOG-
specific T cell receptors and retinal ganglion cells-restricted CFP were 150 ng B. pertussis toxin on Days 0 and 2 and demyelination was
augmented following injection of 250mg demyelinating antibody on Day 14. Animals were injected intraperitoneally daily with either
vehicle or 10 mg/kg carbamazepine or oxcarbazepine in ethanol:cremophore:PBS vehicle from Days 0–21. Animals were sacrificed and the
eyes removed on Day 21 and retinal flat mounts were prepared and the number of retinal ganglion cells within the retina were counted.
(A and B) Retinal ganglion cells in oxcarbazepine-treated animals at (A) low and (B) higher power. (C) Retinal ganglion cells in a vehicle-
treated animal at high power. (D) Retinal ganglion cells number stereologically counted in either normal (n = 24) animals or mice induced
to develop optic neuritis and treated either with vehicle (n = 14) or carbamazepine (n = 7) in one experiment or vehicle (n = 22) or
oxcarbazepine (n = 13) in a separate experiment. Results represent the mean  SEM. *P50.05, **P5 0.01, ***P50.001 compared
with vehicle-treated animals.
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Therefore local delivery to injured neurons of p-glycoprotein
substrates that are normally excluded from the CNS may allow
selective targeting of drugs to EAE and multiple sclerosis lesions.
Production of a lesion-targeting
central nervous system-excluded,
sodium-channel blocking agent
A series of sodium channel blockers were synthesized (Clutterbuck
et al., 2009), and to test our hypothesis, we generated a number
of molecules, of which, CFM6104 [N-((5-(2-(2-(1h-imidazol-1-
yl)ethyl)-2h-indazol-3-yl)-1,2,4-oxadiazol-3-yl)methyl)-3-methyl-
benzamid] exhibited moderately favourable pharmacokinetic
properties (Browne et al., submitted for publication). This molecule
was predicted to be traceable using fluorescence because of the
presence of an indazole group in the structure and had a blood/
brain partition coefficient (Rishton et al., 2006) of 0.72 that
would predict 80% CNS exclusion. Using membranes trans-
fected with human ABCB1 (Fig. 6A) and a Caco-2 bioassay
(Table 1) the compound was found to be a p-glycoprotein sub-
strate and, accordingly, its transport was facilitated by the p-glyco-
protein inhibitor cyclosporin A. These findings indicated that the
transporter would normally actively remove CFM6104 from the
CNS. When administered intravenously, CFM6104, failed to ex-
hibit marked brain penetration at Cmax indicative of CNS exclusion
following intravenous administration (Table 2). The intraperitoneal
route gave a better duration of action than the oral route and was
used for in vivo studies. Following intraperitoneal injection of
CFM6104 to ABH mice there was 490% exclusion in the spinal
cord (Table 3). In EAE there was no apparent enhancement of
CNS penetration, despite a significantly (P5 0.001) higher
plasma level than in healthy animals (Table 3). This is probably
related to a slowing of drug metabolism following the develop-
ment of hypothermia that develops in the mice during periods of
immobility during active EAE (Al-Izki et al., 2012). However, as
CFM6104 was a naturally fluorescent compound, it could be
traced. It was found to be excluded from the CNS in normal ani-
mals (Fig. 6B and C) but was able to access inflammatory lesions
in the spinal cords of EAE animals (Fig. 6D and E). This indicated
that the drug was indeed targeting and penetrating lesions,
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Figure 4 Selective loss of p-glycoprotein in EAE lesions. (A)
Expression of p-glycoprotein in the spinal cord of normal animals
detected by indirect immunoperoxidase staining. Dashed line
indicates border of normal white matter (NWM) and normal grey
matter (NGM). (B) Loss of vascular expression in an infiltrated
perivascular lesion during relapse phase EAE. (C) Loss of vascular
expression of p-glycoprotein in acute EAE lesion. (D) BCRP
expression in a perivascular lesion in EAE. (E–G) Lesion in acute EAE.
(F) High power of subpial lesion with loss of p-glycoprotein ex-
pression from E. (G) High power of non-inflamed blood vessel ex-
pressing p-glycoprotein from E. (H–N) Immunofluorescence
Figure 4 Continued
staining demonstrating loss of p-glycoprotein. (E) Loss of p-glyco-
protein expression in the perivascular lesion during EAE. Lesion in
the white matter of spinal cord of mice stained to detect (H) p-
glycoprotein or (I) DAPI. (J and K) Higher power of the EAE lesion
depicted in H and I. The figure demonstrates selective loss of p-
glycoprotein within lesions and demonstrates the lumen of the
blood vessel indicated the presence of endothelia within the
section. (L–N) Spinal cord from progressive EAE during remission
from active paralysis. Although active inflammation may be less
(L) DAPI staining, (M) endothelia detected through FITC-detected
glucose transporter Glut-1 may (open arrow) or may not (filled
arrow) co-express (N) p-glycoprotein-detected using
rhodamine-labelled antibodies.
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Figure 5 Selective loss of p-glycoprotein in multiple sclerosis lesions. (A–E) Indirect immunoperoxidase staining using diaminobenzidine
substrate and haematoxylin counterstain of (A) control (heart attack) human brain, (B–K) multiple sclerosis brain, (B) blood vessel in
normal appearing white matter (NAWM) and (C) chronic inactive multiple sclerosis lesion. (D) Low magnification of D showing chronic
inactive lesion containing vessels that lack p-glycoprotein and astrocytes expressing p-glycoprotein and surrounding normal appearing
white matter. (E) The expression of BCRP is maintained within lesions in a chronic active lesion and surrounding normal-appearing white
matter. (F–K) Indirect immunofluorescence staining of p-glycoprotein in (F–H) normal appearing white matter and (I–K) active multiple
sclerosis lesion. Sections were stained with (F and I) DAPI, (G and J) Glut-1 to detect endothelia (H and K) and rhodamine detected
p-glycoprotein. (G and H) In normal appearing white matter endothelia clearly express p-glycoprotein. (J and K) In active lesions
endothelia may downregulate p-glycoprotein.
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presumably by a mechanism involving downregulation of p-glyco-
protein at the blood–brain barrier in the vicinity of lesions.
Neuroprotective effect of a central
nervous system-excluded, lesion
targeting sodium-channel blocker
The dominant antigen in spinal cord-induced EAE in ABH mice is
within the proteolipid protein that gives a poor in vitro prolifera-
tive response (Pryce et al., 2005; Smith et al., 2005). Therefore,
the immunosuppressive effect of CFM6104 on T cell function
was investigated using a simple contact-hypersensitivity paradigm
that has been used to identify in vivo immunosuppressive doses
(Watson et al., 1991; Baker et al., 1992; O’Neill et al., 1992).
Compared with vehicle treatment, CMF6104 failed to inhibit
lymph node proliferative responses after daily intraperitoneal
administration of 5 mg/kg, 25 mg/kg and 50 mg/kg from a day
before sensitization to the time of collecting the lymph nodes
(Browne et al., submitted for publication). Therefore, it was felt
unnecessary to dose-titrate CFM6104 to avoid any immunosup-
pression-induced neuroprotection that could mask any real neuro-
protective action of this drug. To limit animal usage required for a
full-dose-response study, we selected 10 mg/kg CFM6104 admin-
istered intraperitoneally as a proof of principle dose. This dose was
within the range used in humans for sodium channel-blocking
agents (1–50 mg/kg per os), particularly when scaled to mouse
and was well below the maximum tolerated dose (450 mg/kg/
daily). Intraperitoneal administration of 10 mg/kg CFM6104 was
used to investigate its neuroprotective potential in an induced-
relapse during EAE. The lack of immunosuppressive activity of
CFM6104 was indicated further by the observation that
CMF6104 did not significantly (P40.05) inhibit the incidence,
onset, or maximum severity of relapsing EAE (Fig. 7A and B).
Although CFM6104 did not inhibit the severity of paralysis
during relapse (Fig. 7A), consistent with a lack of overt lymphoid
cell immunosuppression, it did promote a significantly (P50.01)
greater degree of recovery of motor-function during remission
(Fig. 7B). This could be seen using the subjective clinical scoring
system (Fig. 7B) and objective motor-function using the RotaRod
(P5 0.001, Fig. 7C). These improved motor outcomes were par-
alleled by the ability of CMF6104 to reduce spinal cord nerve loss,
a consequence of relapsing disease, as assessed by an ELISA spe-
cific for neurofilament, (Fig. 7D). Therefore, CMF6104 did exhibit
a neuroprotective effect and slowed the loss of nerves due to
inflammatory attack.
Discussion
This study provides further evidence that Nav blockers have the
potential to limit nerve loss in the progressive phase of EAE.
Although this finding is not novel, this current study differs from
many in that the clinical activity is not simply secondary to an
immunosuppressive action exerted within the CNS (Lo et al.,
2003; Black et al., 2007). In the present study the compounds
were delivered to sensitized animals with disease at a time that
does not to interfere with priming of T cells and at a dose with no
overt T cell immunosuppression; based on the clinical profile and
ex vivo T cell assays as shown with carbamazepine, oxcarbama-
zepine and CFM6104. Interestingly, inhibition of T cell responses
was not seen either with boluses of 1, 10 and 30 mg/kg phenytoin
(50 mg/kg was toxic) (unpublished observation) or in the rat with
lamotrigine (Bechtold et al., 2006) and contrasts with that seen
with peripherally-active immunosuppressive agents (Baker et al.,
1992; O’Neill et al., 1993). Although we have not seen immuno-
suppressive activity in the Nav blockers we examined, such an
activity could be of additional benefit in arresting autoimmune-
dependent neurodegeneration. It has been shown that prophylac-
tic peripheral immunosuppression can account for the protection
of EAE (Black et al., 2007), however, therapeutic doses of agents
used here were not overtly T cell immunosuppressive. The degree
of inflammation was not directly measured in the EAE as clinical
Table 1 Compounds (1 kM) assayed for monolayer
permeation using CacoReadyTM assay
Efflux ratio (external versus internal)
Drug Drug alone Drug + CacoReadyTM
assay
Atenolol 0.3 Not done
Pindolol 1.3 Not done
Propanolol 0.8 Not done
Indinavir ( + control) 38.5 1.34
CFM6104 41.1 2.72
Caco2 cells were grown on a membrane; compounds were added to the apical or
basolateral compartments and assayed in those compartments by LC-MS 2 h later.
Drug concentrations were quantified by LC-MS/MS.
Table 2 Pharmacokinetics of CFM6104 assessed using
LC-MS in mice injected with 5mg/kg intravenous or
10mg/kg intraperitoneal CFM6104
Mean CFM6104 levels (pg/ml)
Time (min) Plasma
(intraperitoneal)
Plasma
(intravenous)
Brain
(intravenous)
5 445  71 1107  32 53.0  0.0
15 373  38 212  6 53.0  0.0
30 129  12 63  24 53.0  0.0
The results show the mean (n = 3) amount of compound detected.
Table 3 Normal ABH or paralysed ABH mice with EAE
(n = 3–4) injected 30min earlier with 10mg/kg
intraperitoneal CFM6104
Mean CFM6104 levels (pg/ml)
Mice Drug n Plasma Spinal cord
Normal Vehicle 4 51.0  0.0 51.0  0.0
Normal CFM6104 4 124.0  34.2 10.0  6.4
EAE CFM6104 3 985.0  90.4* 18.9  6.8
The results represent mean  SEM levels. * P5 0.05 compared to normal mice.
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course was the primary outcome measure; however, the degree of
inflammation directly correlates with the severity of clinical disease
during disease development and is dynamic such that inflamma-
tory infiltrates are lost as animals begin to remit (Baker et al.,
1990, 2011; Allen et al., 1993; Wujek et al., 2002; Jackson
et al., 2009). In this study there was no indication of immunosup-
pression of the generation of inflammation as assessed histologi-
cally in the uveitis model and by the fact that the onset and
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Figure 6 CMF6104 is a CNS-excluded, p-glycoprotein substrate that penetrates EAE lesions. (A) Vehicle, verapamil (100 mM) and
CFM6104 (100 mM) were tested as substrates for p-glycoprotein assessed in the Pgp-Glow assay. The results represent the mean  SEM
(triplicates) bioluminescence measurements from the luciferin reporter. The inset shows the structure of CFM6104. (B–E) Cryostat sections
of spinals cords from animals injected 30 min earlier with 20 mg/kg intraperitoneal CFM6104 and perfused with PBS before collection of
spinal cords (E–G) paralysed (grade 4 and losing weight) EAE mice or (E) a normal mouse. (B) EAE section stained with DAPI (blue)
demonstrating lesions (white dashed line), (C) extravasation of CFM6104 (green) in the same lesions or (D and E) double staining for DAPI
and CFM6104.
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severity of clinical disease was unaffected. However, inhibition of
peripheral immunity preventing lesion formation (Black et al.,
2007) in addition to anti-inflammatory effects within the CNS
once lesions form (Bechtold et al., 2006; Morsali et al., 2013)
and direct neuroprotection by an action on nerves (Fern et al.,
1993; Garthwaite et al., 1999; Kapoor et al., 2003) will contribute
to the overall neuroprotective potential of this class of agents.
Clinical trials in multiple sclerosis of sodium channel blockers
have been halted because of concern about a rebound effect
following cessation of treatment that occurred in animals
(Black et al., 2007; Waxman, 2008). This can occur when im-
munosuppressive doses of compounds that prevent disease devel-
opment are removed, which allows CNS autoimmunity to return
(Greenwood et al., 2003; Black et al., 2007). As the compounds
reported here were found not to be immunosuppressive and did
not inhibit the generation of relapse, we would not anticipate, and
did not look for, a rebound effect following cessation of treat-
ment. However, in the absence of peripheral immunosuppression,
sodium channel blockade also induces a neuroprotective anti-
inflammatory effect through inhibition of microglial function
(Bechtold et al., 2006; Morsali et al., 2013). Lamotrigine treat-
ment resulted in what was thought to be pseudoatrophy in brain
volume because of some anti-inflammatory effect reducing tissue
oedema (Kapoor et al., 2010). Following cessation of lamotrigine
treatment brain volume increased suggestive of some return of
disease activity, but this was not associated with a rebound
exacerbation in secondary progressive multiple sclerosis (Kapoor
et al., 2010).
We have previously demonstrated that the neurofilament ELISA
provides a good correlate to histological assessment of axon num-
bers (Jackson et al., 2005, 2009; Al-Izki et al., 2012) and neuro-
filament release into biological fluids as a consequence of nerve
damage is a reliable biomarker for neurodegeneration in people
with multiple sclerosis and other disorders (Gunnarsson et al.,
2011; Gnanapavan et al., 2013). Neurofilament measurement
offers the advantage of rapid analysis of the whole spinal cord
and provides an outcome measure that can be translated into
human disease (Gunnarsson et al., 2011; Gnanapavan et al.,
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Figure 7 CFM6104 inhibits the accumulation of neurological deficit and neurodegeneration during EAE. ABH mice were injected with
1 mg mouse spinal cord homogenate in Freund’s adjuvant on Days 0 and 7 post induction to induce EAE and this was repeated on Day 27
post induction to induce a relapse. Animals were injected intraperitoneally daily with either vehicle or 10 mg/kg CFM6104 from Day 33
onwards. Animals were monitored for the development of clinical disease and the results represent: (A) the mean maximal clinical score,
during the initial acute attack Days 15–20 and the clinical relapse Days 34–40, or the mean minimal clinical score during remission from
paralytic attacks. (B) The mean daily clinical score following induction of relapse. (C) The time taken to fall from an accelerating RotaRod
was monitored pre-treatment on Day 25 or on Day 48 post-disease induction, when the experiment was terminated. (D) The spinal cords
were removed and nerve content was measured using a neurofilament heavy chain (Nfh)-specific ELISA. The results represent the
mean  SEM of eight animals per group. *P50.05, **P50.01, ***P50.001 compared with vehicle-treated animals.
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2012, 2013). This technique lacks the bias associated with the use
of histological analysis, which is not only time-consuming but in-
variably focuses analysis on restricted-CNS tracts. Any marked
neuroprotection by Nav blockers in sensory tracts may not be re-
flected in the motor outcomes measures (Lo et al., 2003; Bechtold
et al., 2006). Clinical scoring systems commonly used in EAE have
been developed to assess active paralysis similar to the Expanded
Disability Status Scale (EDSS) that is used for multiple sclerosis.
These are subjective, user-dependent and are subject to bias of
analysis, as treatment effects are greater in studies not reporting
blinding (Vesterinen et al., 2010). Furthermore, they are non-
linear scales that are insensitive to change. This is especially the
case in assessing functional deficits in animals that occur as a
consequence of paralytic attacks (Al-Izki et al., 2012). However,
residual neurological deficit after attack can be used to detect
neuroprotective effects (Baker et al., 2011). More importantly
the accelerating RotaRod appears to be a sensitive, objective
and quantitative outcome measure that can detect motor deficits
and functional improvements during remission from paralytic at-
tacks (Al-Izki et al., 2011, 2012). This shows a strong correlation
with spinal nerve content (Al-Izki et al., 2012). These two out-
comes together showed significant treatment responsiveness to
Nav blockade. In addition, the use of the novel optic neuritis
model provides a further tool to confirm the neuroprotective ef-
fects of sodium channel blockers.
Although it has been reported that the Nav blocker lamotrigine
is ineffective in progressive multiple sclerosis (Kapoor et al., 2010),
it is premature to discard this class of agents on the basis of this
result. Lamotrigine did not appear to influence the course of mul-
tiple sclerosis, except perhaps by slowing the decline in the 25 m
walk (Kapoor et al., 2010). However, lamotrigine in comparison
with other compounds is a weak neuroprotectant in vitro
(Garthwaite et al., 1999). In preclinical EAE studies (group sizes
of n = 70), lamotrigine demonstrated a marginal (P50.05) clinical
improvement and histological analysis of selected sensory nerve
tracts showed a 30% reduction in axonal loss in a subset (50%
of animals) of the experimental animals (Bechtold et al., 2006).
Moreover, in a trial in patients with multiple sclerosis, the primary
MRI outcome measure of cerebral volume was complicated by
accelerated atrophy in the first year as mentioned previously.
Unfortunately, the trial was too short to accommodate pseudoa-
trophy in a positive fashion (Kapoor et al., 2010). Furthermore,
the patient cohort may not have been optimal for this study. The
disease in the placebo group was slowly progressing with few
clinical changes from baseline. Importantly, the drug was also
poorly tolerated (Kapoor et al., 2010). This was indicated by the
high number of drop-outs during the study, the inability of many
to reach the target anti-epileptic dose because of side effects and
most importantly, the observation that 40–50% of patients in
the active arm were not drug-compliant as defined by serum levels
(Kapoor et al., 2010; Gnanapavan et al., 2013; Raftopoulos and
Kapoor, 2013). Therefore, it is not surprising that the main study
failed to show a drug effect. Nevertheless, there was a significant
reduction in serum neurofilament levels between placebo and
drug-compliant individuals, indicating that Nav blockage was neu-
roprotective (Gnanapavan et al., 2013), as found here in EAE.
Therefore, study of people with multiple sclerosis at earlier
stages of their disease, when they can better tolerate Nav block-
age is warranted.
We demonstrate that Nav blockade is neuroprotective in a novel
experimental optic neuritis model that exhibits subclinical EAE and
offers a less severe, 3Rs-refined alternative to classical paralytic
EAE. Both oxcarbazepine and carbamazepine inhibited the conse-
quences of optic neuritis in the optic nerve that is reflected by loss
of retinal ganglion cells in the retina (Bettelli et al., 2003; Guan
et al., 2006). This is consistent with the neuroprotective effect of
5 mg/kg intraperitoneal of CFM6104 in the same model and treat-
ment paradigm that produced significant (P50.05) neuroprotec-
tion of retinal ganglion cells (Browne et al., submitted for
publication). This concept is currently being tested in an optic
neuritis trial (Raftopoulos and Kapoor, 2013).
Although a desired mechanism for treatment of progressive
multiple sclerosis is through prevention of sodium loading in
nerves (Dutta and Trapp, 2011), the neuroprotective influence
found here is probably anti-inflammatory within the CNS. While
the data may suggest that such sodium channel blockade may
have some benefit in the control of progression, the results of
the current study are best translated to treatment during relapsing
multiple sclerosis. Further studies to examine the influence in post-
relapsing secondary progressive EAE (Al-Izki et al., 2011) are war-
ranted to explore the neuroprotective potential of sodium channel
blockade for progressive multiple sclerosis. That p-glycoprotein is
lost in chronic inactive lesions, where blood–brain barrier dysfunc-
tion is reduced, may allow neuroprotection of demyelinated nerves
to be targeted. These are particularly vulnerable to damage due to
metabolic demands required to maintain conduction following
rearrangement of Nav1.6 from the nodes of Ranvier during
demyelination (Craner et al., 2004). Low levels of these receptors
are expressed along the length of demyelinated axons and the
novel expression of Nav1.2 occurs on these nerves to maintain
conduction (Craner et al., 2004). Local targeting of axonal con-
duction in areas of myelin-denuded axon may, however, still cause
some negative symptomatic deficits because of impedance mis-
match and through influences of low density of sodium channels
on demyelinated axons (Waxman and Brill, 1978). Although the
risk of this is perhaps reduced compared to the globally active fully
penetrant CNS compounds, side effects were not noticed during
this study; however, the aim was not to induce toxicity and there-
fore low doses of compounds were used. Nevertheless, it was
noted that although doses of 50 mg/kg intraperitoneal CFM6104
were well tolerated, phenytoin induced toxicity and caused fatality
at the same dose, supporting the concept that CNS-excluded
compounds may have a better tolerability profile.
It is known that Nav blockers inhibit macrophage and microglial
activation (Black and Waxman, 2012; Morsali et al., 2013).
Through this mechanism, the neurodegenerative effect of the
inflammatory-penumbra that is formed around the perivascular
lesions by T cell invasion correlates in time with the period of
active blood–brain barrier dysfunction. In mice, this ‘inflammatory
penumbra’ lasts for a few days and correlates with the period of
time that the blood–brain barrier is disrupted. In humans, it is
likely to be longer because acute inflammatory multiple sclerosis
lesions are known to enhance with gadolinium on MRI, signifying
blood–brain barrier dysfunction for a few weeks (Butter et al.,
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1991; Cotton et al., 2003; Al-Izki et al., 2012). For this reason we
are recruiting and dosing volunteers for the acute optic neuritis
study (NCT01451593; Raftopoulos and Kapoor, 2013) within
14 days of disease onset, when lesions would have focal disruption
of the blood–brain barrier as detected with gadolinium-enhanced
MRI. Furthermore, as there are many more MRI lesions than clin-
ical attacks the approach of selectively targeting lesions is import-
ant even when the disease is in apparent clinical remission.
Although our studies may indicate an anti-inflammatory effect,
which may occur in multiple sclerosis as seen by a reduction in
tissue oedema (Kapoor et al., 2010), this is unlikely to be because
of a lymphoid cell immunosuppressive effect that is hypothesized
to drive relapsing disease. Therefore, an optimal therapeutic strat-
egy may require a combination of a systemic immunosuppressive
agent combined with a neuroprotective agent. We initially exam-
ined carbamazepine, which has side effects such as drowsiness,
dizziness, ataxia and nausea in humans. However, oxcarbazepine,
which is an analogue of carbamazepine, was slightly more active
as a neuroprotectant in our hands and has a lower incidence of
side effects and is therefore better tolerated (Elger and Bauer,
1998). We therefore plan to use oxcarbazepine in another novel
trial (Protective Role of OXcarbazepine In MUltiple Sclerosis or
PROXIMUS study) that will use neurofilament levels in serial
CSF analyses as the primary outcome measure. This provides an-
other example of how animal studies can help inform the devel-
opment of new treatments for people with multiple sclerosis.
Loss of p-glycoprotein expression in multiple sclerosis has
been independently confirmed and it has been shown that
p-glycoprotein is lost in active, chronic active and chronic inactive
multiple sclerosis lesions (Kooij et al., 2010, 2011). Blockade of
p-glycoprotein enhances brain penetration of p-glycoprotein sub-
strates as shown using PET (Nojiri et al., 2008) and therefore loss
of vascular p-glycoprotein may potentially allow targeting of acute
multiple sclerosis lesions similarly to the way in which active EAE
lesions were targeted here. Despite this potential benefit for
pharmacotherapy, loss of p-glycoprotein expression may contrib-
ute to the neurotoxicity that drives progression of the disease.
Downregulation of p-glycoprotein occurs after CD54 cross-linking
associated with leucocyte diapedesis (Kooij et al., 2010). However,
there are other factors that regulate p-glycoprotein expression
(Miller et al., 2008) and loss of p-glycoprotein is observed in
both chronic active and importantly chronic inactive lesions,
which are not all associated with perivascular cuffing as shown
here. Therefore, Nav blocking agents that are p-glycoprotein sub-
strates would be able to inhibit both the progressive neurodegen-
erative processes in nerves and the glial cell activation that drive
neurodegeneration in vivo. We have produced a Nav blocker that
was selectively CNS-excluded and traceable. However, LC-MS stu-
dies failed to demonstrate CFM6104 penetration during EAE,
which was surprising because active disease is associated with
blood–brain barrier dysfunction in the spinal cord (Al-Izki et al.,
2012). This suggests that either only small amounts were pene-
trating the lesions or that CNS CFM6104 was not being detected
because of technical reasons such as binding of the hydrophobic
compound to CNS structures, (e.g. myelin) or it was rapidly meta-
bolized in the brain. However, the compound could be seen to
penetrate the lesions and this had an action consistent with CNS
penetration and may indicate that only small amounts of
compound are required for a biological effect.
Current Nav blockers, given their general hydrophobicity, may
be expected to show some affinity for ABC efflux transporters and
thus may partially exploit this targeting approach (Crowe and
Teoh, 2006; Nakanishi et al., 2013). CFM6104 is a CNS-excluded
p-glycoprotein substrate and yet it clearly targeted lesions during
EAE and induced neuroprotection. Although CFM6104 was suffi-
cient to provide proof of principle, further development of this
class of compound is warranted to improve potency at the
target and predicted pharmacokinetic profile. This selective target-
ing strategy could be developed for other drugs, where global
CNS penetration and receptor stimulation may be problematic,
and provides new avenues for future treatment of multiple
sclerosis.
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